EZH2 and non-small cell lung carcinoma: Riquelme et al. showed that in KRASG12C-mutant NSCLC, EZH2 expression was preferentially upregulated through the MEK–ERK signaling pathway [35], and a negative prognostic association of EZH2 overexpression has been proposed in several human malignancies, including NSCLC [29,30,31,32,33,34,35].